ArticleFrontiers in immunology2025
Multi-omics profiling unravel the immune landscape diversity by prognostic signatures of immunotherapy response in triple-negative breast cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The role of KIAA1467 in breast cancer: insights from pan-cancer and single-cell sequencing analysis.Translational cancer research · 2026Article
- Spatial organization of the TNBC tumor microenvironment: multicellular niches, T-cell bottlenecks, and therapeutic opportunities.Journal of translational medicine · 2026Review
- Beyond Molecular Classification in Metastatic Triple-Negative Breast Cancer: Toward Subtype-Guided Precision Oncology.International journal of molecular sciences · 2026Review
- AI-driven multi-omics integration in breast cancer: clinical applications, immunotherapy prediction, and translational challenges.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) remains a challenging malignancy with limited therapeutic options and variable responses to immune checkpoint inhibitors (ICIs). The tumor immune infiltration significantly influences the outcomes of immunotherapy treatments. Novel biomarkers are urgently needed which integrate both tumor-intrinsic and immune-related features to better stratify patients and dissect the immune microenvironment. Methods: We investigated the tumor immune infiltration and assessed its prognostic significance in an internal cohort of TNBC patients using multiplex immunofluorescence. Then we integrated multi-omics approach that combines bulk and single-cell RNA sequencing to develop a prognostic signature. The model underwent validation across three independent external cohorts and additional immunotherapy cohorts. Immune cell infiltration was assessed using CIBERSORT, and cellular communication networks were characterized through CellChat analysis. Expression and functional investigations of key genes were conducted in TNBC cell lines using knockdown and overexpression techniques and further functional assays. Results: Our internal cohort of patients with TNBC revealed distinct TIME profiles and both high CD8 Conclusions: We developed and validated an immune-related signature for predicting TNBC outcomes and immunotherapy response. This signature reflects underlying immune landscape heterogeneity and provides a crucial method for patient stratification and immunotherapeutic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.